H1 2024 Checkpoint Landscape Review

In the first half of 2024, the checkpoint inhibitor landscape has witnessed significant shifts, with a 10% increase in immune checkpoint modulators (ICMs) driven by the rise of next-generation targets like STING and B7-H3.

Our H1 2024 Landscape Review offers crucial insights into the evolving checkpoint space, including the initiation of new clinical trials and the growing focus on emerging targets. Understanding these developments is essential for maintaining a competitive edge.

Part 1 – The Drug Landscape

Download Here

Part 2 – The Trial Landscape & Regulatory Announcements

Coming Soon

Part 3 – The Commercial Landscape & Future of Checkpoint

Coming Soon

What do these reviews cover?

The 2024 Checkpoint Landscape Review delivers a detailed analysis of the current state of the checkpoint field, covering:

The Drug Landscape – Explore the emergence of 2,045 ICMs, with a 10% increase in new assets, highlighting the shift towards novel targets and the persistent interest in PD-1 and CTLA-4 inhibitors.
The Trial Landscape & Regulatory Announcements – Gain insights into the 1,189 new clinical trials launched this year, with a focus on adaptive trial designs, biomarker-driven patient selection, and the ongoing challenges of advancing new therapies without recent approvals.
The Commercial Landscape & Future of Checkpoint – Understand the cautious yet strategic investment trends of 2024, where late-stage PD-1 and PD-L1 inhibitors dominate funding, while early-phase investment is funneled into emerging targets like STING and ADORA2A.

Find out more

Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.

Each dataset features proprietary, hyper-relevant search and filtering tailored to specific modalities, in-depth data, plus additional market insight curated by our subject matter experts. Beacon is here to support you in making these decisions with confidence through our encompassing database solution.

With Beacon, you can make drug development decisions with confidence. This is why 23 out of the world’s top 25 drug developers trust us.

Discover more about Beacon